Recent Updates
Recently added Catalysts
ALGN Positive Sentiment

Align Technology Prevails in China Patent Infringement Action Against Angelalign

Wednesday, August 12, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Align Technology has achieved a legal victory in a patent infringement case against Angelalign in China. The Jinan Intermediate People's Court ruled in favor of Align, affirming its intellectual property rights. This decision is expected to bolster Align's competitive stance in the Chinese market.

Market Sentiment Analysis

POSITIVE FACTORS

  • Align Technology won a significant patent infringement case.
  • The judgment reinforces Align's intellectual property rights.
  • This victory may strengthen Align's market position in China.

Full Press Release Details

SAN JOSE, Calif. & TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. ("Align") (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, today announced that the Jinan Intermediate People's Court in China issued a judgment in favor of Align in a patent infringement action against Angelalign Technology's operating subsidiaries in China ("Angel") (Hong Kong Stock Exchange: 6699.HK). In September 2025, Align filed a

Frequently Asked Questions

What was the outcome of Align's patent case?

Align Technology won the patent infringement case against Angelalign in China.

Which court ruled in favor of Align Technology?

The Jinan Intermediate People's Court in China issued the ruling.

What does this ruling mean for Align Technology?

The ruling reinforces Align's intellectual property rights and market position.

When was the patent infringement case filed?

Align filed the patent infringement case in September 2025.

ShareAdd on Google
Tags: ALGN Viatris Investor Conferences Healthcare Align Technology Angelalign patent infringement China medical device
Last updated: Aug 12, 2026

Biotech snapshot

Cash runway
$1103M liquidity · $0M/mo burn
Low dilution risk